Current developments in molecular monitoring in chronic myeloid leukemia.
Molecular monitoring plays an essential role in the clinical management of chronic myeloid leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse-transcriptase-polymerase-chain-reaction (qRT-PCR) assessment of BCR-ABL1 transcript levels has become the standard of care protocol in CML. However, further developments are required to assess leukemic burden more efficiently, monitor minimal residual disease (MRD), detect mutations that drive resistance to tyrosine kinase inhibitor (TKI) therapy and identify predictors of response to TKI therapy. Cartridge-based BCR-ABL1 quantitation, digital PCR and next generation sequencing are examples of technologies which are currently being explored, evaluated and translated into the clinic. Here we review the emerging molecular methods/technologies currently being developed to advance molecular monitoring in CML.
Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
Justine Ellen
JE
Marum
Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
Susan
S
Branford
BCR-ABL1; Next-generation sequencing; chronic myeloid leukemia; digital PCR; minimal residual disease; molecular monitoring; qRT-PCR; resistance mutations
N Engl J Med. 1999 Jul 15;341(3):164-72
10403855
Nucleic Acids Res. 2012 Jun;40(11):e82
22373922
Genomics Proteomics Bioinformatics. 2015 Oct;13(5):278-89
26542840
Blood. 2012 Mar 1;119(9):1981-7
22228624
Blood. 2016 Jun 2;127(22):2773-4
27076173
Br J Haematol. 2014 Jul;166(1):3-11
24754670
Blood. 2016 Apr 14;127(15):1870-80
26773037
Blood. 2008 Oct 15;112(8):3330-8
18684859
Blood. 2013 Jan 17;121(3):489-98
23223358
Ann Oncol. 2015 Jan;26(1):64-70
25319062
Cancer Cell. 2014 Sep 8;26(3):428-442
25132497
Br J Haematol. 1999 Dec;107(3):587-99
10583264
Science. 2001 Aug 3;293(5531):876-80
11423618
Leuk Lymphoma. 2011 May;52(5):896-904
21338281
J Clin Invest. 2007 Sep;117(9):2562-9
17710227
Blood. 2010 Nov 25;116(22):e111-7
20720184
Haematologica. 2014 Sep;99(9):1441-7
24837466
Blood. 2012 Mar 8;119(10):2234-8
22210874
Blood Rev. 2006 Jan;20(1):29-41
16426942
Blood. 2012 Apr 12;119(15):3403-12
22371878
Lancet. 2002 Feb 9;359(9305):487-91
11853795
PLoS One. 2015 Jul 01;10(7):e0128916
26132974
Blood. 2011 Nov 10;118(19):5250-4
21908430
Braz J Med Biol Res. 1996 Oct;29(10):1307-10
9181101
J Mol Diagn. 2016 Mar;18(2):176-89
26857065
Clin Chem. 2008 Sep;54(9):1568-71
18641042
Br J Haematol. 1995 Mar;89(3):546-54
7734353
Arch Pathol Lab Med. 2007 Jun;131(6):947-50
17550324
Cell. 1986 Oct 24;47(2):277-84
3021337
Am J Hum Genet. 1989 Nov;45(5):729-38
2683759
Haematologica. 2014 Mar;99(3):458-64
24362549
Leukemia. 1991 Nov;5(11):937-41
1961034
Cancer Lett. 2013 Nov 1;340(2):192-200
23376639
Blood. 2003 Jul 1;102(1):276-83
12623848
Blood. 2012 Jul 12;120(2):291-4
22645182
Clin Chem. 2007 Sep;53(9):1593-600
17660274
J Clin Oncol. 2009 Dec 10;27(35):6041-51
19884523
Ann Hematol. 2010 Mar;89(3):241-7
19714331
Int J Lab Hematol. 2010 Dec;32(6 Pt 1):e222-8
20491997
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
10430926
J Clin Oncol. 2014 Feb 10;32(5):415-23
24297946
Probl Radiac Med Radiobiol. 2015 Dec;20:328-40
26695912
BMC Cancer. 2015 Feb 12;15:45
25880391
J Clin Oncol. 2014 Feb 10;32(5):424-30
24323036
Blood. 2010 Aug 26;116(8):1329-35
20462961
Eur J Haematol. 2016 Apr;96(4):360-6
26059983
J Clin Oncol. 2012 Jan 20;30(3):232-8
22067393
Blood. 2014 Jul 3;124(1):153-5
24993880
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S120-8
26297264
Blood. 2012 May 3;119(18):4264-71
22431575
Blood. 2016 Feb 11;127(6):703-12
26603839
Leukemia. 2015 Feb;29(2):369-76
25036192
Blood. 2013 Aug 8;122(6):872-84
23803709
Blood. 2014 Jul 24;124(4):511-8
24859364
Blood. 2008 Feb 15;111(4):1774-80
18055868
Leukemia. 2015 May;29(5):999-1003
25652737
Blood. 2013 Aug 29;122(9):1634-48
23794064
Br J Haematol. 1995 May;90(1):138-46
7786776
J Mol Diagn. 2014 Mar;16(2):174-9
24389534
Haematologica. 2009 Oct;94(10):1362-7
19713230
Blood. 2009 Dec 3;114(24):4944-53
19779040
Nucleic Acids Res. 1989 Oct 11;17(19):7631-42
2678002
Med Oncol. 2015 Feb;32(2):452
25579165
Lancet Oncol. 2010 Nov;11(11):1029-35
20965785
Haematologica. 2009 Sep;94(9):1227-35
19608684
Blood. 2011 Aug 4;118(5):1208-15
21562040
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13
22853953
Haematologica. 2011 May;96(5):664-71
21330326
Ann Oncol. 2015 Jun;26(6):1180-1187
25712455
Leukemia. 2009 Feb;23(2):396-9
18615105
Leukemia. 2015 May;29(5):1123-32
25676422
Oncoscience. 2014 Jul 23;1(7):510-21
25594053
Blood. 2012 Oct 18;120(16):3382-3
23086624
J Mol Diagn. 2015 Mar;17(2):185-92
25554588
Leukemia. 2010 Oct;24(10):1719-24
20811403
Mol Cancer. 2015 Apr 18;14:89
25928096
Nat Rev Clin Oncol. 2016 Jun;13(6):335-47
26483300
Blood. 2011 Dec 22;118(26):6760-8
22039253
J Clin Oncol. 2011 Nov 10;29(32):4250-9
21990409
Biotechniques. 1999 Jan;26(1):112-22, 124-5
9894600
Nat Methods. 2015 May;12(5):423-5
25849638
Clin Cancer Res. 1999 Dec;5(12):4146-51
10632353
Mol Med Rep. 2013 Feb;7(2):591-7
23151810
J Clin Oncol. 2009 Sep 1;27(25):4204-10
19652056
Blood. 2006 Jul 1;108(1):28-37
16522812
J Mol Diagn. 2007 Apr;9(2):220-7
17384214
Pathology. 2015 Oct;47(6):570-4
26166664
Eur J Cancer. 2014 Mar;50(4):793-800
24365090
Leuk Res. 2014 Mar;38(3):310-5
24333114
Haematologica. 1992 Jan-Feb;77(1):16-20
1398276
Leukemia. 2012 Sep;26(9):2096-102
22446502
Blood. 2016 Mar 10;127(10):1269-75
26729897
Ann Lab Med. 2016 May;36(3):287-9
26915625
Blood. 2009 Sep 10;114(11):2232-5
19531657
Leukemia. 1992 Sep;6(9):948-51
1518306
Oncogene. 2015 Sep 10;34(37):4845-54
25500544